These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 31679643)
21. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775 [TBL] [Abstract][Full Text] [Related]
22. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760 [TBL] [Abstract][Full Text] [Related]
23. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
24. Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials. Zhu Y; Shen X; Jiang Q; Wang Z; Wang Z; Dong X; Li J; Han Q; Zhao J; Wang B; Liu L Herz; 2019 Jun; 44(4):336-346. PubMed ID: 29116337 [TBL] [Abstract][Full Text] [Related]
25. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. Zhang XL; Zhu QQ; Zhu L; Chen JZ; Chen QH; Li GN; Xie J; Kang LN; Xu B BMC Med; 2015 Jun; 13():123. PubMed ID: 26099511 [TBL] [Abstract][Full Text] [Related]
28. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study. Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724 [TBL] [Abstract][Full Text] [Related]
29. Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention. Choi IJ; Lim S; Lee D; Lee WJ; Lee KY; Kim MJ; Jeon DS Am J Cardiol; 2020 Oct; 133():54-60. PubMed ID: 32798044 [TBL] [Abstract][Full Text] [Related]
30. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. Farmakis I; Doundoulakis I; Pagiantza A; Zafeiropoulos S; Antza C; Karvounis H; Giannakoulas G J Cardiovasc Pharmacol; 2021 Mar; 77(3):397-407. PubMed ID: 33298738 [TBL] [Abstract][Full Text] [Related]
31. In-hospital initiation of a PCSK9 inhibitor in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials. Shi W; Xu Y; Zhou L; Wang W; Huang W; Zhou B Medicine (Baltimore); 2024 Mar; 103(10):e37416. PubMed ID: 38457555 [TBL] [Abstract][Full Text] [Related]
32. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. Brandt EJ; Benes LB; Lee L; Dayspring TD; Sorrentino M; Davidson M J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):54-61. PubMed ID: 29940784 [TBL] [Abstract][Full Text] [Related]
33. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252 [TBL] [Abstract][Full Text] [Related]
34. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement]. Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076 [TBL] [Abstract][Full Text] [Related]
35. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796 [TBL] [Abstract][Full Text] [Related]
36. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis]. Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908 [TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. Ridker PM; Revkin J; Amarenco P; Brunell R; Curto M; Civeira F; Flather M; Glynn RJ; Gregoire J; Jukema JW; Karpov Y; Kastelein JJP; Koenig W; Lorenzatti A; Manga P; Masiukiewicz U; Miller M; Mosterd A; Murin J; Nicolau JC; Nissen S; Ponikowski P; Santos RD; Schwartz PF; Soran H; White H; Wright RS; Vrablik M; Yunis C; Shear CL; Tardif JC; N Engl J Med; 2017 Apr; 376(16):1527-1539. PubMed ID: 28304242 [TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. Talasaz AH; Ho AJ; Bhatty F; Koenig RA; Dixon DL; Baker WL; Van Tassell BW Pharmacotherapy; 2021 Dec; 41(12):1009-1023. PubMed ID: 34657313 [TBL] [Abstract][Full Text] [Related]
40. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]